Kersten MJ, Dreyling M, Linton KM, Chitu D, Zwezerijnen GJ, Tonino SH, Kap M, Liu R, van Hooije C, Chamuleau ME, Visser HP, de Jongh E, Marijt EA, Leys MB, Bilgin YM, Dürig J, McKay P, Snijders T, Pettitt A, Minnema MC, Prange-Krex G, Cuijpers ML, Bohmer LH, Tick LW, Florschutz A, Silbermann M, Fijnheer R, Beeker A, Tolboom N, Mitea C, Arens AI, Wiegers SE, Heymans MW, Klapper W, Coupland SE, de Jong D, Doorduijn JK, Zijlstra JM. Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study. haematol [Internet]. 2020Sep.10 [cited 2026Apr.19];. Available from: https://haematologica.org/article/view/14120